Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on May 20, 2020, reporting events occurring on May 12, 2020. The Company, an emerging growth company incorporated in Delaware, operates in the pharmaceutical sector. The filing details a new financing arrangement involving the sale of accounts receivable to improve liquidity.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for a reporting period. Instead, it discloses specific transaction metrics related to an accounts receivable purchase agreement:
- Transaction Type: Recourse sale of accounts receivable.
- Counterparty: Oasis Capital, LLC.
- Initial Face Amount Sold: $2,753,639.
- Purchase Price Received: $1,032,000 (approximately 37.5% of face value).
- Threshold Price: $1,182,000 (calculated as Purchase Price plus 5.45% of face amount).
- Transaction Fees: $25,000 initial fee, with potential additional fees up to $5,000 per future transaction.
Material Changes and Obligations
The Company entered into a Purchase Agreement with Oasis Capital, LLC, creating a new liability structure tied to receivables collection:
- Recourse Obligation: If the purchaser collects less than the Threshold Price ($1,182,000) on the initial batch, Jaguar Health must either pay the shortfall in cash or assign additional receivables equal to the shortfall plus a 25% penalty.
- Overage Sharing: If collections exceed the Threshold Price, the excess is returned to the Company within five days.
- Servicing: Jaguar Health and its subsidiary, Napo Pharmaceuticals, Inc., will continue to service and administer the sold accounts.
- Term: The agreement has an initial one-year term with automatic renewal unless terminated with 30 days' notice (or 60 days' notice for early termination).
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance on revenue or earnings. However, it outlines significant contractual risks and contingencies:
- Change of Control Restrictions: The agreement requires purchaser consent for any material change in beneficial ownership or change of control.
- Asset Disposition Restrictions: Consent is required for the sale of substantially all assets or any merger/consolidation.
- Right of First Offer: The purchaser holds a right of first offer on future sales, financing, or factoring of the Company's accounts.
- Indemnification: The Company has agreed to indemnify the purchaser for certain losses related to the agreement or purchased accounts.
Investor Verification Checklist
- Verify the current status of the $2,753,639 in receivables sold and whether the Threshold Price of $1,182,000 has been met.
- Review the full text of the Purchase Agreement (Exhibit 10.1) to understand the specific recourse triggers and penalty calculations.
- Assess the impact of the 37.5% discount on face value on the Company's effective cost of capital.
- Monitor for any future transactions under this agreement that may trigger additional transaction fees.
- Check subsequent filings for any cash payments made to cover shortfalls or additional receivables assigned to the purchaser.